The Rx Advocates’ Post

Healthcare Secrets 🔍💉🏥 Diabetes 🩸 Diabetes is often misdiagnosed, but a promising insulin is on the horizon! 🩸 All doctors recognize that weight loss can cure type 2 diabetes. Insulin tends to store fat in fat cells for those with diabetes. Many doctors aren't aware of type 1.5 diabetes (Partial Pancreatic Deficiency), a mix of type 1 and 2. Also called LADA, it starts like type 2 but progresses to insulin needs, resembling type 1. Treated with long-lasting insulin. Recognize the signs like high blood sugar and excessive urination in non-obese patients. Exciting news! Better weekly insulin drugs are on there way. 🌟 #DiabetesAwareness #InsulinAdvancements #Type2Diabetes #LADA #MedicalBreakthrough #HealthNews #WeightLossCures #PatientEducation #InnovativeTreatment #WeeklyInsulin #MedicalResearch

 #cocreatedwithSanofi #SanofiMedical We all know the importance of finding the right medication for our diabetes management. Did you know that each insulin has its own personality and characteristics? Let’s dive deeper into the key differences between long and longer-acting basal insulin. Uncover fundamental attributes that underpin clinical efficacy, guiding patient choice towards optimal diabetes management. Evaluate duration of action of different basal insulins in relations to PK/PD profiles. Examine glycemic variability across different insulin types. Discover how different insulin types impact hypoglycemia risk and unveil the nuances in their safety profiles. #InsulinDifferentiation #BloodSugarManagement #DiabetesTreatment #InsulinPharmacokinetics #GlycemicVariability #Hypoglycemia #BasalInsulin

✨ Breakthrough for Patients with Medication Adherence Challenges ✨ Trelagliptin, a once-weekly DPP-4 inhibitor, is revolutionizing type 2 diabetes management for patients who struggle with medication adherence. Medication adherence is a significant challenge for many patients, leading to suboptimal treatment outcomes and increased healthcare costs. With Trelagliptin's once-weekly dosing, patients can now enjoy improved glucose control and reduced cardiovascular risk with fewer dosing burdens. This breakthrough offers new hope for patients who have struggled with daily or multiple daily doses, enabling them to better manage their condition and improve their quality of life. #MSL #MedicalAffairs #GetzPharma

#cocreatedwithSanofi #SanofiMedical   We all know the importance of finding the right medication for our diabetes management. Did you know that each insulin has its own personality and characteristics? Let’s dive deeper into the key differences between long and longer-acting basal insulins • Uncover fundamental attributes that underpin clinical efficacy, guiding patient choice towards optimal diabetes management • Evaluate duration of action of different basal insulins in relations to PK/PD profiles • Examine glycemic variability across different insulin types • Discover how different insulin types impact hypoglycemia risk and unveil the nuances in their safety profiles   #InsulinDifferentiation #BloodSugarManagement #DiabetesTreatment #InsulinPharmacokinetics #GlycemicVariability #Hypoglycemia #BasalInsulin

🎉 Exciting breakthrough in PAH treatment: FDA approves WINREVAIR! 🎉 @Merck has just received the green light from the FDA for WINREVAIR, fantastic news for adults battling Pulmonary Arterial Hypertension (PAH). Let's break it down: 😍 Innovative Therapy: It's the first of its kind, targeting a brand-new pathway in PAH treatment. Just imagine.... opening a new door to better breathing and heart health!!!!! 🏃♂️ Boosted Exercise Capacity: Patients can look forward to not just walking further but feeling better. SIGNIFICANTLY improving exercise ability. 🚀 Rapid Improvements: Alongside standard treatments, it dramatically enhances quality of life, reducing risks of disease progression. 💡 Safety Checks: Regular monitoring ensures that treatment with WINREVAIR stays on the safe side, focusing on hemoglobin and platelet counts. Keep an eye out - it's hitting specialty pharmacies by the end of April! #PAH #WINREVAIR #HealthcareInnovation #FDAApproval #Merck

Discover how incorporating patient-reported outcomes (#PROMs) can boost medication adherence! 🩺💊 Experts share insights on using PROMs to improve the health of patients with advanced liver disease. Learn more about successful strategies and real-world applications. Read the full article: https://loom.ly/osJMX0M #Healthcare #PatientOutcomes #MedicationAdherence #LiverDisease #Pharmacy

Pulmonary Arterial Hypertension (PAH) is a chronic condition that affects the blood vessels connecting the heart to the lungs. It is caused by narrowing or blockage of these vessels, leading to increased pressure in the lungs. This puts strain on the heart and can eventually result in heart failure. Treatment options for PAH have significantly improved in the last decade with the introduction of new medications. While there is no cure, the disease can be managed effectively with medication. Regular monitoring, including blood tests, is necessary to track the progression of the disease. Early treatment is crucial as PAH can worsen quickly if left untreated. Adhering to prescribed treatment regimens can help slow symptom progression. Due to the complexity of treatment, PAH should be managed by experienced healthcare providers at specialized treatment centers. #Menagen #pharma #PAH

Daily Critical Care Pearls #172: Heparin-induced Thrombocytopenia - Part 2 📌 For a patient diagnosed with HIT who has just begun warfarin, you can give full dose anticoagulation with an appropriate agent and hold the warfarin and reverse it with vitamin K. 📌 For a patient with obesity, it is preferred to use argatroban as the chosen anticoagulant for managing HIT. Monitoring aPTT 2 or 3 hours after the rate change is appropriate based on the half-life, but consider extending this in patients with hepatic dysfunction to account for the longer half-life in such patients. #criticalcare #clinicalpharmacy #medicine #pearls

📢 See the Tide of Your Diabetes: Understanding C-Peptide Levels Managing diabetes effectively requires accurate information about your body's insulin production. The C-Peptide test offers a clear picture of how much insulin your body is making, enabling precise diabetes management. 🔍 Why C-Peptide Testing is Important: Accurate Assessment: Provides an exact measure of insulin production. Tailored Treatment: Helps doctors create personalized treatment plans. Better Management: Offers insights into whether you're producing enough insulin naturally. 📏 The Process: The C-Peptide test involves a simple blood sample, analyzed to determine your body's insulin production. It's a crucial tool for both Type 1 and Type 2 diabetes patients. 🏭 Beneficiaries: Diabetes Patients: Get a clear understanding of your insulin levels. Healthcare Providers: Develop more effective, individualized treatment strategies. Stay informed and proactive in your diabetes management. Consider getting your C-Peptide levels checked today! #DiabetesCare #DiabetesManagement #Health #Wellness #Cpeptide #InsulinLevels #HealthcareInnovation #PersonalizedMedicine #ApolloSugar

Breakthroughs in Type 1 Diabetes Research | Sernova | Airing on BNN Bloomberg Sernova is making significant strides in the treatment of type 1 diabetes with its cutting-edge clinical trials. Their groundbreaking approach has led to multiple patients achieving insulin independence and maintaining long-term blood sugar control within the non-diabetic range. This promising development could mark a major advancement in diabetes management, offering hope to millions affected by the condition. As Sernova continues its research, the future looks bright for those seeking more effective diabetes treatments. (TSX: SVA, OTCQB: SEOVF) Learn More: https://lnkd.in/eMT6FwZE #Diabetes #DiabetesTreatment #BloodSugarControl #ClinicalTrials #HealthcareStocks #StocksinFocus #StockstoWatch